C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.

C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.

C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.

C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.

C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.

C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.

C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.

C. Michael Gibson and Bruno Scheller discuss 1-year outcomes of two parallel RCTs.

Junjie Zhang and C. Michael Gibson discuss 3-year outcomes after IVUS- versus angiography-guided DES implantation.

Gregg Stone and C. Michael Gibson discuss a randomized trial examining interventional treatment of vulnerable plaques.